Efficacy of androgen deprivation therapy and the role of oxidative stress

被引：6
|
作者：
Price, D. K. [1 ]
机构：
[1] Natl Canc Inst, Natl Inst Hlth, Genitourinary Malignancies Branch, Bethesda, MD USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷 / 03期
基金：
美国国家卫生研究院;
关键词：
RESISTANT PROSTATE-CANCER; INCREASED SURVIVAL; MITOXANTRONE; PREDNISONE;
D O I：
10.1093/annonc/mdx001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：451 / 453
页数：4
相关论文
共 50 条
  • [21] Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel
    Yu, Wandong
    Li, Junhong
    Wang, Qiang
    Wang, Boshi
    Zhang, Li
    Liu, Yun
    Tang, Ming
    Xu, Guiqing
    Yang, Zhaojuan
    Wang, Xilong
    Zhang, Jun
    Liu, Yongzhong
    Shi, Guowei
    PROSTATE, 2019, 79 (11) : 1304 - 1315
  • [22] Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis
    Ayer Botrel, Tobias Engel
    Clark, Otovio
    Lima Pompeo, Antonio Carlos
    Horta Bretas, Francisco Flavio
    Sadi, Marcus Vinicius
    Ferreira, Ubirajara
    dos Reis, Rodolfo Borges
    PLOS ONE, 2016, 11 (06):
  • [23] Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy
    Kalina, Jennifer L.
    Neilson, David S.
    Comber, Alexandra P.
    Rauw, Jennifer M.
    Alexander, Abraham S.
    Vergidis, Joanna
    Lum, Julian J.
    CANCERS, 2017, 9 (02)
  • [24] Positive surgical margins: The argument for androgen deprivation and chemotherapy
    Higano, Celestia S.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (01) : 89 - 91
  • [25] Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer
    Yang, David D.
    Mahal, Brandon A.
    Muralidhar, Vinayak
    Martin, Neil E.
    Orio, Peter F.
    Mouw, Kent W.
    King, Martin T.
    Choueiri, Toni K.
    Quoc-Dien Trinh
    Hoffman, Karen E.
    Spratt, Daniel E.
    Feng, Felix Y.
    Nguyen, Paul L.
    EUROPEAN UROLOGY, 2019, 75 (01) : 35 - 41
  • [26] Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate Cancer
    Bertaglia, Valentina
    Tucci, Marcello
    Fiori, Cristian
    Aroasio, Emiliano
    Poggio, Massimiliano
    Buttigliero, Consuelo
    Grande, Susanna
    Saini, Andrea
    Porpiglia, Francesco
    Berruti, Alfredo
    CLINICAL GENITOURINARY CANCER, 2013, 11 (03) : 325 - +
  • [27] Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
    Fizazi, Karim
    Faivre, Laura
    Lesaunier, Francois
    Delva, Remy
    Gravis, Gwenaelle
    Rolland, Frederic
    Priou, Frank
    Ferrero, Jean-Marc
    Houede, Nadine
    Mourey, Loic
    Theodore, Cnristine
    Krakowski, Ivan
    Berdah, Jean-Francois
    Baciuchka, Marjorie
    Laguerre, Brigitte
    Flechon, Aude
    Ravaud, Alain
    Cojean-Zelek, Isabelle
    Oudard, Stephane
    Labourey, Jean-Luc
    Chinet-Charrot, Paule
    Legouffe, Eric
    Lagrange, Jean-Leon
    Linassier, Claude
    Deplanque, Gael
    Beuzeboc, Philippe
    Davin, Jean-Louis
    Martin, Anne-Laure
    Habibian, Muriel
    Laplanche, Agnes
    Culine, Stephane
    LANCET ONCOLOGY, 2015, 16 (07) : 787 - 794
  • [28] Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate
    Giacinti, Silvana
    Carlini, Paolo
    Roberto, Michela
    Bassanelli, Maria
    Strigari, Lidia
    Pavese, Francesco
    Aschelter, Anna M.
    Felici, Alessandra
    Valeriani, Maurizio
    Cognetti, Francesco
    Marchetti, Paolo
    ANTI-CANCER DRUGS, 2017, 28 (01) : 110 - 115
  • [29] Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer
    Iwamoto, Hiroaki
    Izumi, Kouji
    Makino, Tomoyuki
    Mizokami, Atsushi
    CANCERS, 2022, 14 (07)
  • [30] A novel GPCR target in correlation with androgen deprivation therapy for prostate cancer drug discovery
    Tian, Jing-Yan
    Chi, Chang-Liang
    Bian, Ge
    Guo, Feng-Jun
    Wang, Xiao-Qing
    Yu, Bing
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 (02) : 195 - 203
12345